NFKB1 and metabolic dysfunction-associated steatotic liver disease: On the other hand, an ameliorative action of sitagliptin in NAFLD was demonstrated via decreasing HMGB1-mediated TLR4/NF-κB signaling, which suppressed inflammation and reduced IR [31].